APPLICATIONS PUBLISHED 21 JULY 2004

Published: 10-Jan-2005

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

  • Fondant-based pharmaceutical compsn
    McNeil-PPC 1438018*

  • Kit for the preparation of a pharmaceutical compsn
    PARI GmBH Spezialisten fuer effektive Inhalation 1438019*

  • Topical compsns and methods for treating pain
    EpiCept 1438020*

  • Methods and apparatus for extrusion of vesicles at high pressure
    Esperion Therapeutics 1438021*

  • Drug delivery system for controlled therapy
    Vista Scientific 1438022*

  • Novel process
    Glaxo Group 1438023*

  • Process for dispersing a fluid in solid particles
    Dow Global Technologies 1438024*

  • Method for the production of active ingredient-containing pellets
    Roehm 1438025*

  • Taste-masking spill-resistant formulation
    Tero Pharmaceutical Industries 1438026*

  • Methods of treatments using a gastric retained losartan dosage
    DepoMed 1438027*

  • Modified release dosage forms
    McNeil-PPC 1438028*

  • Method and system for non-vascular sensor implantation
    Medtronic Minimed 1438029*

  • Modified release dosage forms
    McNeil-PPC 1438030*

  • Orally administered liquid compsns comprising guaifenesin and a polyalkylene block copolymer
    Procter & Gamble 1438031*

  • Production of starch-gel-based shaped bodies
    Innogel 1438032*

  • Hard capsules based on polysaccharides and method for the production thereof
    Innogel 1438033*

  • Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
    Gruenenthal 1438034*

  • Pharmaceutical compsns for the treatment of urinary disorders
    Pharmacia 1438035*

  • Use of sulphonamide derivatives as pharmaceutical compounds
    Eli Lilly 1438036*

  • Methods for treating dry eye by a combination of an anti-inflammatory steroid and a MUC-1 secretagogue
    Alcon 1438037*

  • Method and compsn for preventing or reducing the symptoms of insulin resistance syndrome
    Interhealth Nutraceuticals 1438038*

  • Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anticancer agent for therapeutic use in cancer treatment
    Societe de Conseils de Recherche et d'Applications Scientifiques (SCRAS) 1438039*

  • Pharmaceutical compsns comprising mycophenolic acid or mycophenolate salt
    Novartis 1438040*

  • Spermicides
    SSL International 1438041*

  • Polymaleimide compounds and their medical use
    SSL International 1438042*

  • Method of reducing type II diabetes in high risk patients
    Aventis Pharma Deutschland 1438043*

  • Bis-heteroaryl alkanes as therapeutic agents
    Transtech Pharma 1438044*

  • Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
    Biovitrum 1438045*

  • Thiazole benzamide derivatives and pharmaceutical compsns for inhibiting cell proliferation, and methods for their use
    Agouron Pharmaceuticals 1438046*

  • Compounds for reducing excessive intake of food
    Boehringer Ingelheim Pharma 1438047*

  • 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
    Boehringer Ingelheim Pharma 1438048*

  • Substituted 4-phenyl-4-(imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
    Janssen Pharmaceutica 1438049*

  • Irinotecan for treatment of cancer
    Epidauros Biotechnologie 1438050*

  • An enantiomerically pure diaryl-methylpiperazine and methods of using same
    Ardent Pharmaceuticals 1438051*

  • Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
    Boehringer Ingelheim Pharma GmbH; Boehringer Ingelheim Pharmaceuticals Inc; Boehringer Ingelheim International GmbH 1438053*

  • Methods and compsns for treating flaviviruses and pestiviruses using 4'-modified nucleoside
    Idenix (Cayman); Centre National de la Recherche Scientifique (CNRS) 1438054*

  • D-tagatose as an anti-biofilm agent
    Spherix 1438055*

  • Drug for treating a fibrotic disease through RNA interference
    Ribopharma 1438056*

  • Pine cone extracts and uses thereof
    Tanaka, Akiko; Jessip, John; Bradley, William 1438057*

  • Extract of Ceratonia siliqua leaves and pods containing polyphenols with antioxidant and antitumour activities
    Baraldi, Mario 1438058*

  • Compsn containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
    Angiolab, Research Centre for Biomedicinal Resources; Kim, Min-Young 1438059*

  • Prevention and treatment of restenosis by local adminstration of drug
    Esperion Therapeutics 1438060*

  • Copolymers for suppression of autoimmune diseases, and methods of use
    President and Fellows of Harvard College 1438061*

  • Methods and compsns for treating dermal lesions
    The General Hospital Corp 1438062*

  • Modulation of physiological processes and agents useful for same
    The Mental Health Research Institute of Victoria 1438063*

  • A method for identification and development of therapeutic agents
    Epipop 1438064*

  • An in vivo animal model of chronic arterial occlusion and use of collagenase to facilitate guide wire crossing in chronic arterial occlusions
    Strauss, Bradley 1438065*

  • Incapacitated whole-cell immunogenic bacterial compsns
    Gangagen 1438066*

  • Autologous growth factor cocktail compsn, method of production and use
    Verigen 1438067*

  • Antibody inhibitors of GDF-8 and uses thereof
    Wyeth 1438068*

  • Enzyme inhibitors for inactivating allergens
    Molecular Skincare 1438069*

  • Treating vascular disease by inhibiting toll-like receptor-4
    Cedars-Sinai Medical Centre 1438070*

  • Therapies for treating respiratory diseases
    Glaxo Group 1438071*

  • Polysaccharide-based network and method for the production thereof
    Innogel 1438072*

  • Polyoxyalkylenes conjugates as enzyme inhibitors
    Procter & Gamble 1438073*

  • Adjuvant compsns
    Chiron 1438074*

  • Methods and compsns relating to restricted expression lentiviral vectors and their applications
    Institut Clayton de la Recherche 1438075*

  • Radiopharmaceutical agent for the treatment of early stage cancer
    Dow Global Technologies 1438076*

  • Methods of sterilising biological materials containing non-aqueous solvents
    Clearant 1438077*

  • Compsn consisting of a polymer containing amino groups and an aldehyde containing at least three aldehyde groups
    Aesculap 1438079*

  • Antibiotic calcium phosphate coating
    Howmedica Osteonics 1438080*

  • You may also like